## Veterinary Chemistry Analyser

## Correlation Study - Preanaesthetic Plus Panel

## Contents

1. Clinical Evaluation Purposes............................................................................................................. 2
2. Product Introduction......................................................................................................................... 2
2.1. Normal Reference Ranges.......................................................................................................... 5
3. Evaluation Method .......................................................................................................................... 6
4. Experimental Procedure..................................................................................................................... 6
4.1. Sample Selection Basis, Inclusion Criteria, Exclusion of Specimens, Rejection Criteria.......... 6
4.2. Quality Control Method ............................................................................................................ 7
4.3. Test Operation.......................................................................................................................... 7
4.4. Data and Statistical Management .............................................................................................. 7
5. Test Results ........................................................................................................................................ 7
5.1. Evaluation Test Results (Default Unit mmol/L): ...................................................................... 7
5.2. Results Statistics and Analysis (TP)......................................................................................... 14
5.3. Results Statistics and Analysis (ALT)..................................................................................... 15
5.4. Results Statistics and Analysis (ALP)...................................................................................... 16
5.5. Results Statistics and Analysis (BUN) ...................................................................................... 17
5.6. Results Statistics and Analysis (CRE) ..................................................................................... 18
5.7. Results Statistics and Analysis (GLU) ..................................................................................... 19
5.8. Results Statistics and Analysis (CK) ....................................................................................... 19
5.9. Results Statistics and Analysis (AST)..................................................................................... 21
5.10. Results Statistics and Analysis (LDH) ................................................................................ 22
6. Clinical Evaluation Conclusion....................................................................................................... 23

Approved By:


Date:
$10 / 9 / 2021$

## 1. Clinical Evaluation Purposes

This clinical evaluation trial is a set of comparison experiments to investigate the equivalence of Preanesthetic Panel Plus and control products on the same set of specimens.

## 2. Product Introduction



Each independently packaged reagent disc is formed by injection moulding a transparent material. A freeze-dried spherical biochemical detection reagent is arranged in the outer periphery of the rotor which is equivalent to a colorimetric device of a conventional biochemical analyser when the optical detection is performed. All blood separation, the mixing of the sample with the diluent and the biochemical reaction were performed on the reagent disc.

There is an injection port on the reagent disc where the sample is introduced. Diluent is released by pulling the aluminium strip on the rotor.

There is a device on the disc to separate the whole blood so the sample can use serum, plasma or anticoagulant whole blood. The disc can accurately quantify the samples and diluents, and the quantitative samples and diluents can be mixed in the mixing tank. Under the action of centrifugal force and capillary force, the sample will be filled with the outer pores of the disk, and the pores will be detected optically after the reaction is completed.

The InSight V-CHEM Preanaesthetic Panel Plus is used to quantitative test the concentration of the nine biochemical indicators in the sample, which is based on the spectrophotometry. The principles are as follows:

## a) Total Protein (TP)

The total protein method is a Biuret reaction, the protein solution is treated with cupric [ Cu (II)] ions in a strong alkaline medium. The $\mathrm{Cu}(\mathrm{II})$ ions react with peptide bonds between the carbonyl oxygen and amide nitrogen atoms to form a coloured Cu-protein complex.

The amount of total protein present in the sample is directly proportional to the absorbance of the Cu-protein complex. The total protein test is an endpoint reaction and the absorbance is measured as the difference in absorbance between 546 nm and 800 nm .

$$
\text { Total Protein }+\mathrm{Cu}(\mathrm{II}) \xrightarrow{\mathrm{OH}^{-}} \text {Cu-Protein Complex }
$$

## b) Alanine Aminotransferase (ALT)

ALT catalyses the transfer of an amino group from L-alanine to a-ketoglutarate to form L-glutamate and pyruvate. Lactate dehydrogenase catalyses the conversion of pyruvate to lactate.
Concomitantly, NADH is oxidised to NAD ${ }^{+}$, as illustrated in the following reaction scheme.

$$
\begin{gathered}
\text { L-Alanine }+ \text { a-Ketoglutarate } \xrightarrow{\text { ALT }} \text { L-Glutamate + Pyruvate } \\
\text { Pyruvate + NADH + } \mathrm{H}^{+} \xrightarrow[L D H]{L} \text { Lactate + NAD }{ }^{+}
\end{gathered}
$$

The rate of change of the absorbance difference between 340 nm and 405 nm is due to the conversion of NADH to $\mathrm{NAD}^{+}$and is directly proportional to the amount of ALT present in the sample.

## c) Aspartate Aminotransferase (AST)

AST catalyses the reaction of L-aspartate and a-ketoglutarate into oxaloacetate and L-glutamate. Oxaloacetate is converted to malate and NADH is oxidised to NAD+ by the catalyst MDH.

$$
\begin{aligned}
& \text { L-aspartate }+ \text { a-ketoglutarate } \xrightarrow{\text { AST }} \text { Oxaloacetate + L-glutamate } \\
& \text { Oxaloacetate }+\mathrm{NADH} \xrightarrow{\text { MDH }} \text { Malate }+\mathrm{NAD}^{+}
\end{aligned}
$$

The rate of absorbance change at 340 /405 nm caused by the conversion of NADH to NAD ${ }^{+}$is directly proportional to the amount of AST present in the sample.

## d) Alkaline Phosphatase (ALP)

Under the catalysis of ALP, the Phosphoric acid on nitrobenzene (4-NNP) was turned into Para nitro phenol (4-NP). 4-NP shows a yellow colour in alkaline solution. At the wavelength of $405 / 505 \mathrm{~nm}$, the ALP activity can be calculated by monitoring the absorbance change rate.

$$
\text { 4-NNP } \xrightarrow{\text { ALP }} \text { Acyl phosphate }+4-\mathrm{NP}
$$

## e) Creatinine (CRE)

In the coupled enzyme reactions, creatinine amidohydrolase (CAH) hydrolyses creatinine to creatine. A second enzyme, creatine amidinohydrolase (CRH), catalyses the formation of sarcosine from creatine. Sarcosine oxidase (SAO) causes the oxidation of sarcosine to glycine, formaldehyde and hydrogen peroxide $\left(\mathrm{H}_{2} \mathrm{O}_{2}\right)$. In a Trinder finish, peroxidase (POD) catalyses the reaction among the hydrogen peroxide, 2, 4, 6-tribromo-3-hydroxybenzoic acid (TBHBA) and 4-aminoantipyrine (4-AAP) into a red quinoneimine dye. Potassium ferrocyanide and ascorbate oxidase are added to the reaction mixture to minimize the potential interference of bilirubin and ascorbic acid respectively.

$$
\begin{gathered}
\text { Creatinine }+\mathrm{H}_{2} \mathrm{O} \xrightarrow{C A H} \text { Creatine } \\
\text { Creatine }+\mathrm{H}_{2} \mathrm{O} \xrightarrow{C R H} \text { Sarcosine + Urea } \\
\text { Sarcosine }+\mathrm{H}_{2} \mathrm{O}+\mathrm{O}_{2} \xrightarrow{\text { SAO }} \text { Glycine + Formaldehyde }+\mathrm{H}_{2} \mathrm{O}_{2} \\
\mathrm{H}_{2} \mathrm{O}_{2}+\text { TBHBA }+4-\text { AAP } \xrightarrow[P O D]{ } \text { Red Quinoneimine Dye }+\mathrm{H}_{2} \mathrm{O}
\end{gathered}
$$

Two cuvettes are used to determine the concentration of creatinine in the sample. Endogenous creatine is measured in the blank cuvette, which is subtracted from the combined endogenous creatine and the creatine formed from the enzyme reactions in the test cuvette. Once the endogenous creatine is eliminated from the calculations, the concentration of creatinine is proportional to the intensity of the red colour produced. The endpoint reaction is measured as the difference in absorbance at 546 nm and 700 nm .

## f) Urea Nitrogen (BUN)

In the coupled-enzyme reaction, urease hydrolyses urea into ammonia and carbon dioxide. Upon combining ammonia with $\alpha$-oxoglutarate and reduced nicotinamide adenine dinucleotide (NADH), the enzyme glutamate dehydrogenase (GLDH) oxidises NADH to NAD+.

$$
\begin{gathered}
\text { Urea }+2 \mathrm{H}_{2} \mathrm{O} \xrightarrow{\text { Urease }} 2 \mathrm{NH}_{4}^{+}+\mathrm{CO}_{3}^{2-} \\
\mathrm{NH}_{4}^{+}+\alpha-\text { Oxoglutarate }+\mathrm{NADH} \xrightarrow[\text { LDDH }]{ } \text { L-Glutamate }+\mathrm{H}_{2} \mathrm{O}+\mathrm{NAD}^{+}
\end{gathered}
$$

The rate of change of the absorbance difference between 340 nm and 405 nm is caused by the conversion of NADH to $\mathrm{NAD}^{+}$and is directly proportional to the amount of urea present in the sample.

## g) Glucose (GLU)

The reaction of glucose with adenosine triphosphate (ATP) catalysed by hexokinase (HK), produces glucose-6-phosphate (G-6-P) and adenosine diphosphate (ADP). Glucose-6-phosphate dehydrogenase (G-6-PDH) catalyses the reaction of G-6-P into 6-phosphogluconate and the reduction of nicotinamide adenine dinucleotide phosphate (NADP ${ }^{+}$) to NADPH.

$$
\begin{gathered}
\text { Glucose + ATP } \xrightarrow[\text { G }]{\text { G-6-P }+\mathrm{NADP}^{+} \xrightarrow[\text { G-6-PDH }]{ } \text { Glucose-6-Phosphate + ADP }} \text { 6-Phosphogluconate + NADPH+ }{ }^{+}
\end{gathered}
$$

The absorbance is measured bichromatically at 340 nm and 405 nm . The production of NADPH is directly proportional to the amount of glucose present in the sample.

## h) Creatine Kinase (CK)

Creatine kinase catalyses the formation of creatine and adenosine triphosphate (ATP) from creatine phosphate and adenosine diphosphate (ADP). With hexokinase (HK) as a catalyst, ATP reacts with Dglucose to form ADP and D-glucose-6-phosphate (G-6-P), which is reacted with nicotinamide adenine dinucleotide phosphate ( $\mathrm{NADP}^{+}$) in the presence of glucose-6-phosphate dehydrogenase (G-6-PDH) to produce 6-Phosphogluconate (6-PG) and NADPH.

The formation of NADPH is measured as a change in absorbance at 340 nm relative to 405 nm . This absorbance change is directly proportional to creatine kinase activity in the sample.

$$
\begin{gathered}
\text { Creatine phosphate + ADP } \xrightarrow{\mathrm{CK}} \text { Creatine + ATP } \\
\text { ATP + D-glucose } \xrightarrow{\mathrm{HK}} \text { ADP + G-6-P } \\
\text { G-6-P + NADP }{ }^{+} \xrightarrow[\text { G-6-PDH }]{ } \text { 6-Phosphogluconate + NADPH + H }{ }^{+}
\end{gathered}
$$

## i) Lactate Dehydrogenase (LDH)

Lactate dehydrogenase (LDH) catalyses the oxidation of L-lactate to pyruvate with the concurrent reduction of nicotinamide adenine dinucleotide $\left(\mathrm{NAD}^{+}\right)$to reduced nicotinamide adenine dinucleotide (NADH). The NADH is then oxidised with the simultaneous reduction of INT in a reaction catalysed by diaphorase. The intensity of the highly coloured formazan is measured bichromatically at 505/800 nm and is directly proportional to the concentration of triglycerides in the sample.

$$
\text { L-Lactate }+\mathrm{NAD}^{+} \xrightarrow{\text { LDH }} \text { Pyruvate }+\mathrm{NADH}+\mathrm{H}^{+}
$$



### 2.1. Normal Reference Ranges

These ranges are provided as a guideline only. It is recommended that your office or institution establish normal ranges for your particular patient population.

| Analyte | SI Units | Common Units |
| :---: | :---: | :---: |
| TP | Dog: $54 \sim 82 \mathrm{~g} / \mathrm{L}$ | Dog: 5.4 ~ 8.2g/dL |
|  | Cat: $54 \sim 82 \mathrm{~g} / \mathrm{L}$ | Cat: 5.4 ~ 8.2g/dL |
| ALT | Dog: $10 \sim 118 \mathrm{U} / \mathrm{L}$ | Dog: $10 \sim 118 \mathrm{U} / \mathrm{L}$ |
|  | Cat: 8.2 ~ 100U/L | Cat: 8.2 ~ 100U/L |
| AST | Dog: $8.9 \sim 48.5 \mathrm{U} / \mathrm{L}$ | Dog: 8.9 ~ 48.5U/L |
|  | Cat: 9.2 ~ 39.5U/L | Cat: 9.2 ~ 39.5U/L |
| ALP | Dog: $20 \sim 150 \mathrm{U} / \mathrm{L}$ | Dog: $20 \sim 150 \mathrm{U} / \mathrm{L}$ |
|  | Cat: 10 ~ 90U/L | Cat: 10 ~ 90U/L |
| CRE | Dog: $27 \sim 118 \mu \mathrm{~mol} / \mathrm{L}$ | Dog: $0.3 \sim 1.3 \mathrm{mg} / \mathrm{dL}$ |
|  | Cat: $27 \sim 141 \mu \mathrm{~mol} / \mathrm{L}$ | Cat: $0.3 \sim 1.6 \mathrm{mg} / \mathrm{dL}$ |
| BUN | Dog: 2.5 ~ 8.9mmol/L | Dog: $7 \sim 25 \mathrm{mg} / \mathrm{dL}$ |
|  | Cat: 3.6 ~ 10.7mmol/L | Cat: $10 \sim 30 \mathrm{mg} / \mathrm{dL}$ |
| GLU | Dog: 3.89 ~ 7.95mmol/L | Dog: $70 \sim 143 \mathrm{mg} / \mathrm{dL}$ |
|  | Cat: 4.11 ~ 8.84mmol/L | Cat: $74 \sim 159 \mathrm{mg} / \mathrm{dL}$ |
| CK | Dog: 20 ~ 200U/L | Dog: 20 ~ 200U/L |
|  | Cat: $50 \sim 450 \mathrm{U} / \mathrm{L}$ | Cat: $50 \sim 450 \mathrm{U} / \mathrm{L}$ |
| LDH | Dog: $40 \sim 400 \mathrm{U} / \mathrm{L}$ | Dog: $40 \sim 400 \mathrm{U} / \mathrm{L}$ |
|  | Cat: 0 ~ 800U/L | Cat: 0 ~ 800U/L |

## 3. Evaluation Method

In this clinical evaluation study, the test system is provided by Woodley Equipment Company Ltd which is composed of an InSight V-CHEM Veterinary Chemistry Analyser and its associated Preanaesthetic Panel Plus containing 9 biochemical detection items. The control system is a detection system consisting of Abaxis VS2 biochemical analyser and profiles.
The evaluation plan is designed with reference to the relevant regulations and authoritative professional guidelines for human medical clinical evaluation. The actual number of samples tested in each project is in line with statistical requirements.

Table 1-1 Number of Completed Projects in this Clinical Evaluation

|  | Comparative test of the same group of serum samples <br> for control and test products |
| :---: | :---: |
| TP | 100 |
| ALT | 100 |
| AST | 100 |
| ALP | 100 |
| CRE | 100 |
| BUN | 100 |
| GLU | 100 |
| CK | 100 |
| LDH | 100 |

## 4. Experimental Procedure

4.1. Sample Selection Basis, Inclusion Criteria, Exclusion of Specimens, Rejection Criteria

The samples used in this clinical evaluation were the daily blood samples of the laboratory for the biochemistry analyser. Specimens that are detectable for the intended use of the test and control products.

According to the daily test results of the hospital and the requirements of the test plan for data distribution, samples that met the requirements were selected. When a range of samples was difficult to collect, two (but no more than two) samples of different concentrations were mixed to obtain a specific range of samples. When it was still difficult to collect a suitable sample using the above mixing method, dilution (salt dilution) was added (increasing the sample reagent ratio) to obtain a specific range of samples.

Selected samples were excluded according to the following a~b criteria:
a) The remaining sample size is less than 0.5 mL , which is not enough to complete the test.
b) The number of samples has exceeded the number of planned tests for the day.

### 4.2. Quality Control Method

During the clinical evaluation process, the control system and the test system were measured before the measurement of the same batch of quality control products to ensure that the test results were under control. Control products and test products are tested daily for quality control before testing samples to ensure that the test results are under control.

### 4.3. Test Operation

Standard samples that met the criteria were selected and divided into two equal parts and tests were performed according to the operating system and test system operating instructions, and test results were recorded.
4.4. Data and Statistical Management

All test results were automatically recorded by the instrument. After the test, they were exported to the pre-designed record form, the original test record of this clinical trial, using Excel software for statistics.

## 5. Test Results

### 5.1. Evaluation Test Results (Default Unit mmol/L):

| V-CHEM reagent value TP g/L | VS2 <br> reagent value TP g/L | V-CHEM reagent value ALT U/L | ```VS2 reagent value ALT U/L``` | V-CHEM reagent value ALP U/L | VS2 <br> reagent value ALP U/L | V-CHEM reagent value BUN | VS2 <br> reagent <br> value BUN | V-CHEM <br> reagent <br> value <br> CRE <br> umol/L | VS2 <br> reagent value <br> CRE umol/L |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 61 | 61.5 | 48 | 50 | 24 | 26 | 5.86 | 6.06 | 45 | 47 |
| 92.8 | 93.3 | 62 | 64 | 23 | 25 | 7 | 7.2 | 216 | 218 |
| 62.2 | 62.7 | 38 | 39 | 56 | 57 | 5.83 | 5.93 | 92 | 93 |
| 58.5 | 58.9 | 67 | 68 | 160 | 161 | 2.83 | 2.93 | 31 | 32 |
| 64.1 | 64 | 89 | 88 | 58 | 57 | 21.2 | 21.1 | 168 | 167 |
| 48.6 | 48.5 | 985 | 982 | 66 | 65 | 5.44 | 5.14 | 63 | 60 |
| 83.7 | 83.8 | 111 | 114 | 24 | 25 | 4.22 | 4.52 | 45 | 48 |
| 73.4 | 73.5 | 87 | 92 | 30 | 32 | 4.25 | 4.75 | 72 | 77 |
| 60.7 | 60.6 | 716 | 721 | 27 | 29 | 20.5 | 21 | 172 | 177 |
| 68.4 | 68.9 | 40 | 45 | 60 | 62 | 7.88 | 8.38 | 119 | 124 |
| 67.9 | 68.3 | 39 | 43 | 16 | 17 | 4.82 | 5.22 | 117 | 121 |
| 69.9 | 69.8 | 264 | 263 | 18 | 17 | 11.5 | 11.4 | 74 | 73 |
| 84.6 | 84.5 | 37 | 36 | 20 | 19 | 3.98 | 3.88 | 85 | 84 |
| 64.5 | 64.6 | 41 | 43 | 14 | 16 | 6.9 | 7.1 | 85 | 87 |
| 79.4 | 79.5 | 67 | 69 | 152 | 154 | 8.11 | 8.31 | 115 | 117 |
| 81.6 | 81.5 | 66 | 64 | 30 | 28 | 2.55 | 2.35 | 65 | 63 |
| 68.1 | 68.6 | 25 | 30 | 20 | 22 | 4.42 | 4.92 | 44 | 49 |


| 57.7 | 58.2 | 28 | 33 | 24 | 26 | 6.1 | 6.6 | 80 | 85 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 62.3 | 62.8 | 43 | 48 | 63 | 65 | 24.6 | 25.1 | 366 | 371 |
| 64.3 | 64.7 | 13 | 17 | 32 | 33 | 14 | 14.4 | 160 | 164 |
| 67.9 | 68 | 84 | 83 | 32 | 31 | 29.9 | 29.8 | 235 | 234 |
| 68.6 | 68.7 | 26 | 25 | 50 | 49 | 18.9 | 18.8 | 187 | 186 |
| 68.8 | 68.7 | 71 | 69 | 59 | 57 | 4.09 | 3.89 | 67 | 65 |
| 75.8 | 76.3 | 53 | 55 | 151 | 153 | 7.37 | 7.57 | 78 | 80 |
| 60.7 | 61.2 | 47 | 46 | 122 | 121 | 14 | 13.9 | 131 | 130 |
| 71.8 | 71.9 | 77 | 79 | 14 | 16 | 4.48 | 4.68 | 89 | 91 |
| 69.9 | 70.3 | 47 | 51 | 53 | 54 | 8.36 | 8.76 | 153 | 157 |
| 66.8 | 67.2 | 50 | 54 | 25 | 26 | 6.62 | 7.02 | 188 | 192 |
| 51.1 | 50.8 | 239 | 236 | 121 | 118 | 29.5 | 29.2 | 328 | 325 |
| 72.3 | 72.4 | 45 | 46 | 26 | 27 | 2.14 | 2.24 | 43 | 44 |
| 68.1 | 68.4 | 61 | 64 | 33 | 36 | 4.46 | 4.76 | 99 | 102 |
| 58.5 | 58.6 | 38 | 39 | 24 | 25 | 6.29 | 6.39 | 68 | 69 |
| 70.6 | 70.7 | 15 | 16 | 21 | 22 | 6.34 | 6.44 | 145 | 146 |
| 64.2 | 64.7 | 27 | 28 | 30 | 31 | 4.4 | 4.5 | 131 | 132 |
| 82.5 | 83 | 105 | 106 | 14 | 15 | 7.11 | 7.21 | 160 | 161 |
| 71.7 | 72.1 | 42 | 40 | 231 | 229 | 15.9 | 15.7 | 167 | 165 |
| 67.8 | 67.9 | 75 | 77 | 131 | 133 | 6.12 | 6.32 | 138 | 140 |
| 63.2 | 63.3 | 69 | 67 | 24 | 22 | 4 | 3.8 | 64 | 62 |
| 64 | 63.9 | 73 | 71 | 54 | 52 | 6.5 | 6.3 | 45 | 43 |
| 66.5 | 67 | 56 | 57 | 24 | 25 | 5 | 5.1 | 73 | 74 |
| 62.6 | 63.1 | 55 | 60 | 528 | 530 | 7.64 | 8.14 | 152 | 157 |
| 61.2 | 61.1 | 62 | 61 | 30 | 29 | 13.2 | 13.1 | 90 | 89 |
| 64.3 | 64.4 | 41 | 42 | 22 | 23 | 7.66 | 7.76 | 64 | 65 |
| 62.5 | 63 | 8 | 7 | 25 | 24 | 2.69 | 2.59 | 68 | 67 |
| 64.7 | 65.2 | 40 | 39 | 25 | 24 | 3.29 | 3.19 | 57 | 56 |
| 53.8 | 54.2 | 151 | 152 | 209 | 210 | 7.33 | 7.43 | 111 | 112 |
| 49.9 | 49.8 | 247 | 248 | 332 | 333 | 11.9 | 12 | 203 | 204 |
| 44.2 | 44.3 | 565 | 566 | 202 | 203 | 8.72 | 8.82 | 218 | 219 |
| 72.9 | 73 | 63 | 64 | 203 | 204 | 6.86 | 6.96 | 132 | 133 |
| 76.9 | 76.8 | 59 | 57 | 33 | 31 | 1.01 | 0.81 | 40 | 38 |
| 65.6 | 66.1 | 45 | 47 | 27 | 29 | 9.04 | 9.24 | 138 | 140 |
| 81.2 | 81.7 | 63 | 61 | 38 | 36 | 6.3 | 6.1 | 39 | 37 |
| 73.1 | 73 | 258 | 257 | 308 | 307 | 4.16 | 4.06 | 98 | 97 |


| 81.8 | 81.9 | 78 | 79 | 14 | 15 | 29.4 | 29.5 | 327 | 328 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 53.6 | 53.7 | 37 | 38 | 26 | 27 | 5.03 | 5.13 | 116 | 117 |
| 59.7 | 59.8 | 31 | 32 | 75 | 76 | 6.63 | 6.73 | 134 | 135 |
| 63 | 63.5 | 184 | 185 | 47 | 48 | 9.29 | 9.39 | 154 | 155 |
| 79.4 | 79.9 | 285 | 284 | 164 | 163 | 7.76 | 7.66 | 234 | 233 |
| 77.6 | 78 | 22 | 24 | 15 | 17 | 4.91 | 5.11 | 81 | 83 |
| 71.8 | 71.7 | 116 | 115 | 28 | 27 | 15.3 | 15.2 | 313 | 312 |
| 69.7 | 69.8 | 108 | 106 | 32 | 30 | 3.88 | 3.68 | 31 | 29 |
| 84 | 84.1 | 43 | 42 | 19 | 18 | 3.15 | 3.05 | 102 | 101 |
| 68.6 | 68.5 | 39 | 44 | 70 | 72 | 7.07 | 7.57 | 112 | 117 |
| 83.4 | 83.9 | 531 | 533 | 1044 | 1046 | 9.47 | 9.67 | 118 | 120 |
| 79.2 | 79.7 | 150 | 155 | 132 | 134 | 7.35 | 7.85 | 146 | 151 |
| 59.4 | 59.3 | 133 | 132 | 109 | 108 | 8.39 | 8.29 | 228 | 227 |
| 75 | 75.1 | 57 | 59 | 28 | 30 | 3.2 | 3.4 | 101 | 103 |
| 62.5 | 62.2 | 148 | 145 | 163 | 162 | 12.2 | 11.9 | 95 | 92 |
| 56.3 | 56.7 | 69 | 73 | 133 | 134 | 5.04 | 5.44 | 97 | 101 |
| 71.6 | 71.7 | 131 | 132 | 24 | 25 | 34.2 | 34.3 | 288 | 289 |
| 57.7 | 57.8 | 77 | 79 | 30 | 32 | 4.32 | 4.52 | 73 | 75 |
| 66.8 | 66.9 | 246 | 247 | 842 | 843 | 9.02 | 9.12 | 239 | 240 |
| 62.5 | 62.6 | 90 | 92 | 21 | 23 | 32.2 | 32.4 | 314 | 316 |
| 65.8 | 66.3 | 211 | 212 | 82 | 83 | 5.6 | 5.7 | 67 | 68 |
| 48.1 | 48.6 | 344 | 345 | 539 | 540 | 17.8 | 17.9 | 347 | 348 |
| 66 | 66.4 | 34 | 33 | 39 | 38 | 7.16 | 7.06 | 122 | 121 |
| 70.7 | 70.8 | 64 | 67 | 28 | 31 | 6.61 | 6.91 | 59 | 62 |
| 64.5 | 64.6 | 23 | 24 | 80 | 81 | 8.58 | 8.68 | 84 | 85 |
| 36.6 | 36.5 | 205 | 203 | 120 | 118 | 19.2 | 19 | 267 | 265 |
| 41.8 | 42.3 | 346 | 349 | 213 | 216 | 28.2 | 28.5 | 393 | 396 |
| 62.6 | 63.1 | 107 | 106 | 18 | 17 | 8.79 | 8.69 | 180 | 179 |
| 75.6 | 76.1 | 166 | 171 | 58 | 60 | 9.27 | 9.77 | 145 | 150 |
| 79.8 | 80.3 | 77 | 82 | 130 | 132 | 5.99 | 6.49 | 76 | 81 |
| 69.2 | 69.6 | 313 | 317 | 25 | 26 | 34.9 | 35.3 | 231 | 235 |
| 56.5 | 56.6 | 33 | 35 | 30 | 32 | 9.16 | 9.36 | 44 | 46 |
| 67.8 | 68.3 | 31 | 36 | 28 | 30 | 8.84 | 9.34 | 114 | 119 |
| 67 | 66.9 | 28 | 26 | 30 | 28 | 15.3 | 15.1 | 184 | 182 |
| 51.9 | 52 | 77 | 78 | 232 | 233 | 8.02 | 8.12 | 50 | 51 |
| 65.2 | 65.3 | 16 | 17 | 27 | 28 | 7.14 | 7.24 | 101 | 102 |


| 44 | 43.9 | 397 | 402 | 109 | 111 | 7.25 | 7.75 | 105 | 110 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 40.8 | 41.3 | 241 | 240 | 76 | 75 | 17.4 | 17.3 | 280 | 279 |
| 61.8 | 62.3 | 48 | 50 | 18 | 20 | 28.1 | 28.3 | 86 | 88 |
| 68.8 | 68.5 | 64 | 61 | 21 | 20 | 9.37 | 9.07 | 84 | 81 |
| 54.8 | 54.7 | 39 | 38 | 52 | 51 | 4.76 | 4.66 | 65 | 64 |
| 63.8 | 64.3 | 70 | 75 | 24 | 26 | 10.2 | 10.7 | 79 | 84 |
| 73 | 73.5 | 80 | 85 | 26 | 28 | 10.5 | 11 | 149 | 154 |
| 71.7 | 72.1 | 216 | 220 | 73 | 74 | 1.95 | 2.35 | 37 | 41 |
| 72.2 | 72.3 | 43 | 45 | 18 | 20 | 29.3 | 29.5 | 253 | 255 |
| 64.9 | 65.4 | 70 | 75 | 74 | 76 | 6.38 | 6.88 | 76 | 81 |
| 62.9 | 62.8 | 36 | 34 | 118 | 116 | 4.05 | 3.85 | 92 | 90 |


| V-CHEM <br> reagent <br> value <br> GLU | VS2 <br> reagent <br> value <br> GLU | V-CHEM <br> reagent <br> value CK <br> U/L | VS2 <br> reagent <br> value CK <br> U/L | V-CHEM <br> reagent <br> value <br> AST U/L | VS2 <br> reagent <br> value <br> AST U/L | V-CHEM <br> reagent <br> value <br> LDH U/L | VS2 <br> reagent <br> value LDH <br> U/L |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 5.73 | 5.56 | 197 | 202 | 41 | 43 | 214 | 213 |
| 5.61 | 5.29 | 196 | 192 | 50 | 52 | 118 | 119 |
| 5.4 | 5.19 | 183 | 181 | 32 | 33 | 150 | 152 |
| 14.59 | 14.51 | 570 | 571 | 33 | 34 | 234 | 237 |
| 14.62 | 14.02 | 546 | 551 | 21 | 20 | 172 | 170 |
| 14.66 | 14.89 | 569 | 572 | 222 | 221 | 126 | 127 |
| 11.06 | 11.31 | 285 | 281 | 61 | 62 | 230 | 232 |
| 5.94 | 6.27 | 206 | 213 | 42 | 44 | 266 | 265 |
| 6.17 | 6.6 | 96 | 92 | 104 | 106 | 695 | 696 |
| 13.25 | 13.17 | 59 | 66 | 22 | 24 | 180 | 182 |
| 6.52 | 5.86 | 96 | 93 | 41 | 45 | 519 | 515 |
| 5.26 | 5.81 | 143 | 149 | 87 | 86 | 134 | 135 |
| 6.15 | 5.56 | 156 | 156 | 16 | 15 | 171 | 170 |
| 6.32 | 5.73 | 34 | 34 | 17 | 19 | 234 | 235 |
| 3.91 | 3.79 | 95 | 96 | 27 | 29 | 134 | 136 |
| 11.93 | 12.38 | 523 | 522 | 48 | 46 | 126 | 125 |
| 7.32 | 7.84 | 96 | 92 | 27 | 29 | 289 | 290 |
| 2.82 | 2.51 | 164 | 161 | 23 | 25 | 178 | 178 |


| 12.19 | 12.8 | 399 | 395 | 14 | 16 | 152 | 151 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 6.85 | 7.36 | 341 | 343 | 72 | 76 | 92 | 91 |
| 16.23 | 16.58 | 259 | 264 | 41 | 40 | 165 | 167 |
| 7.68 | 7.63 | 213 | 220 | 72 | 71 | 392 | 393 |
| 7.48 | 6.94 | 240 | 245 | 38 | 36 | 237 | 236 |
| 5.65 | 5.53 | 180 | 175 | 16 | 18 | 169 | 172 |
| 5.84 | 6.03 | 200 | 199 | 21 | 20 | 240 | 239 |
| 6.47 | 6.97 | 75 | 77 | 80 | 82 | 213 | 214 |
| 6.43 | 6.99 | 200 | 207 | 36 | 40 | 200 | 201 |
| 4.75 | 5.05 | 185 | 186 | 12 | 16 | 158 | 159 |
| 4.79 | 4.57 | 239 | 238 | 61 | 58 | 188 | 188 |
| 5 | 5.35 | 68 | 70 | 27 | 28 | 246 | 247 |
| 6.47 | 6.15 | 166 | 163 | 23 | 26 | 260 | 257 |
| 5.3 | 5.58 | 428 | 428 | 32 | 33 | 1290 | 1291 |
| 8.1 | 7.57 | 147 | 146 | 27 | 28 | 191 | 193 |
| 22.51 | 21.9 | 579 | 582 | 21 | 22 | 119 | 117 |
| 4.96 | 4.33 | 102 | 103 | 51 | 52 | 303 | 302 |
| 6.25 | 6.17 | 277 | 284 | 24 | 22 | 284 | 285 |
| 3.12 | 3.41 | 48 | 52 | 40 | 42 | 131 | 130 |
| 4.42 | 4.92 | 99 | 105 | 48 | 46 | 239 | 237 |
| 5.39 | 5.97 | 94 | 97 | 25 | 23 | 120 | 121 |
| 6.2 | 5.64 | 184 | 181 | 32 | 33 | 166 | 168 |
| 8.16 | 8.35 | 538 | 544 | 42 | 44 | 265 | 257 |
| 6.19 | 6.53 | 83 | 88 | 25 | 24 | 202 | 203 |
| 6.49 | 6 | 225 | 221 | 18 | 19 | 118 | 116 |
| 5.82 | 6.1 | 113 | 117 | 25 | 24 | 130 | 131 |
| 5.76 | 5.43 | 90 | 85 | 15 | 14 | 1213 | 1215 |
| 4.54 | 4.64 | 202 | 202 | 75 | 76 | 385 | 386 |
| 5.85 | 5.5 | 104 | 102 | 105 | 106 | 280 | 278 |
| 6.9 | 7.03 | 388 | 390 | 344 | 345 | 177 | 178 |
| 5.96 | 5.66 | 142 | 149 | 18 | 19 | 222 | 225 |
| 5.67 | 6.17 | 154 | 161 | 20 | 18 | 231 | 230 |
| 5.12 | 5.06 | 114 | 116 | 39 | 41 | 228 | 229 |
| 5.93 | 5.39 | 164 | 166 | 29 | 27 | 209 | 207 |


| 5.35 | 4.89 | 642 | 649 | 28 | 27 | 143 | 140 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 3.73 | 3.83 | 93 | 97 | 32 | 33 | 211 | 211 |
| 5.56 | 5.05 | 136 | 143 | 69 | 70 | 106 | 107 |
| 7.31 | 6.74 | 230 | 237 | 37 | 38 | 482 | 483 |
| 5.35 | 5.63 | 71 | 70 | 61 | 62 | 845 | 847 |
| 7.78 | 7.72 | 230 | 234 | 50 | 49 | 118 | 119 |
| 7 | 6.87 | 116 | 118 | 31 | 33 | 131 | 130 |
| 10.86 | 11.44 | 184 | 187 | 50 | 49 | 1235 | 1236 |
| 6.58 | 6.81 | 83 | 79 | 24 | 22 | 117 | 119 |
| 8.5 | 9.05 | 119 | 122 | 20 | 19 | 194 | 196 |
| 5.16 | 4.67 | 191 | 188 | 29 | 31 | 424 | 428 |
| 15.74 | 16.05 | 57 | 53 | 386 | 388 | 144 | 142 |
| 6.63 | 6.71 | 118 | 116 | 37 | 39 | 117 | 118 |
| 6.1 | 5.5 | 45 | 40 | 20 | 19 | 772 | 778 |
| 4.26 | 3.73 | 64 | 63 | 23 | 25 | 377 | 378 |
| 6.26 | 6.71 | 116 | 123 | 28 | 27 | 140 | 142 |
| 4.91 | 5.28 | 142 | 143 | 21 | 25 | 426 | 424 |
| 6.25 | 6.42 | 32 | 28 | 78 | 79 | 1410 | 1411 |
| 4.96 | 4.98 | 154 | 155 | 38 | 40 | 152 | 150 |
| 5.21 | 5.2 | 109 | 114 | 89 | 90 | 377 | 375 |
| 5.67 | 5.75 | 218 | 220 | 23 | 25 | 25 | 26 |
| 5.36 | 5.18 | 209 | 216 | 103 | 104 | 177 | 175 |
| 4.84 | 5.25 | 87 | 90 | 166 | 167 | 395 | 398 |
| 5.38 | 5.98 | 32 | 32 | 78 | 77 | 690 | 692 |
| 5.51 | 5.18 | 300 | 298 | 35 | 38 | 3128 | 3139 |
| 4.85 | 4.77 | 187 | 192 | 23 | 24 | 125 | 126 |
| 11.47 | 11.64 | 740 | 740 | 678 | 676 | 816 | 815 |
| 6.12 | 6.32 | 177 | 177 | 717 | 720 | 90 | 89 |
| 5.51 | 5.4 | 304 | 309 | 23 | 22 | 181 | 182 |
| 6.14 | 6.68 | 156 | 159 | 35 | 37 | 536 | 535 |
| 6.45 | 6.08 | 36 | 33 | 47 | 49 | 700 | 693 |
| 5.85 | 6.37 | 367 | 367 | 50 | 54 | 526 | 526 |
| 4.71 | 5.28 | 153 | 148 | 87 | 89 | 690 | 695 |
| 7.84 | 7.56 | 282 | 283 | 23 | 25 | 540 | 546 |

(InSight V-CHEM ${ }^{\circ}$

| 4.55 | 4.43 | 105 | 109 | 29 | 27 | 306 | 305 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 7.54 | 7.88 | 298 | 298 | 92 | 93 | 625 | 624 |
| 5.57 | 5.39 | 176 | 182 | 23 | 24 | 832 | 826 |
| 16.66 | 16.51 | 429 | 430 | 671 | 673 | 502 | 502 |
| 3.22 | 2.97 | 370 | 372 | 566 | 565 | 390 | 392 |
| 9.23 | 8.67 | 137 | 135 | 38 | 40 | 709 | 712 |
| 5.47 | 5.81 | 189 | 193 | 46 | 45 | 286 | 286 |
| 6.45 | 6.27 | 690 | 691 | 22 | 21 | 390 | 388 |
| 9.59 | 10.21 | 429 | 424 | 50 | 52 | 260 | 262 |
| 5.94 | 5.33 | 61 | 60 | 17 | 19 | 512 | 513 |
| 8.95 | 8.8 | 704 | 701 | 40 | 44 | 636 | 636 |
| 5.82 | 6.06 | 70 | 74 | 123 | 125 | 434 | 438 |
| 14.57 | 14.96 | 394 | 401 | 32 | 34 | 628 | 625 |
| 4.37 | 4.26 | 143 | 139 | 46 | 44 | 771 | 772 |

### 5.2. Results Statistics and Analysis (TP)

Data Mapping: Plot the difference between the measured value of the test system and the control system, and the measured value of the control system (the centre horizontal line is zero) and the measured system scatter plot (linear regression graph) of the test system and the control system. The results are shown below.

5.2.1. Visually Measure Linearity and Calculate Correlation Coefficient

The visual test system and the control system showed no outliers.
The correlation coefficient between the test system and the control system is calculated to be $r=0.9996$, which is greater than 0.975 . The range of values is appropriate and the correlation and consistency are good.

### 5.2.2. Linear Regression Analysis

Calculated regression equation $y=1.0028 x+0.0334$

### 5.2.3. Statistical Analysis

The t-test was performed on the linear regression equations of the test system and the control system, and the $t$ value was $>t 0.05, \mathrm{P}<0.05$. There was a good linear relationship between the two groups of data, no significant difference.

### 5.3. Results Statistics and Analysis (ALT)

Data Mapping: Plot the difference between the measured value of the test system and the control system, and the measured value of the control system (the centre horizontal line is zero) and the measured system scatter plot (linear regression graph) of the test system and the control system. The results are shown below.



### 5.3.1. Visually Measure Linearity and Calculate Correlation Coefficient

The visual test system and the control system showed no outliers.
The correlation coefficient of the test system and the control system is calculated to be $r=0.9998$, which is greater than 0.975 . The range of values is appropriate and the correlation and consistency are good.

### 5.3.2. Linear Regression Analysis

Calculated regression equation $y=0.9992 x+1.3352$

### 5.3.3. Statistical Analysis

The t-test was performed on the linear regression equations of the test system and the control system, and the $t$ value was $>t 0.05, \mathrm{P}<0.05$. There was a good linear relationship between the two groups of data, no significant difference.

### 5.4. Results Statistics and Analysis (ALP)

Data Mapping: Plot the difference between the measured value of the test system and the control system, and the measured value of the control system (the centre horizontal line is zero) and the measured system scatter plot (linear regression graph) of the test system and the control system. The results are shown below.


### 5.4.1. Visually Measure Linearity and Calculate Correlation Coefficient

The visual test system and the control system showed no outliers.
The correlation coefficient between the test system and the control system is calculated to be $r=0.9999$, which is greater than 0.975 . The range of values is appropriate and the correlation and consistency are good.

### 5.4.2. Linear Regression Analysis

Calculated regression equation $y=1.0008 x+0.5142$

### 5.4.3. Statistical Analysis

The t-test was performed on the linear regression equations of the test system and the control system, and the $t$ value was $>\mathrm{t} 0.05, \mathrm{P}<0.05$. There was a good linear relationship between the two groups of data, no significant difference.

### 5.5. Results Statistics and Analysis (BUN)

Data Mapping: Plot the difference between the measured value of the test system and the control system, and the measured value of the control system (the centre horizontal line is zero) and the measured system scatter plot (linear regression graph) of the test system and the control system. The results are shown below.


### 5.5.1. Visually Measure Linearity and Calculate Correlation Coefficient

The visual test system and the control system showed no outliers.
The correlation coefficient between the test system and the control system is $r=0.9995$, which is greater than 0.975 . The range of values is suitable and the correlation and consistency are good.

### 5.5.2. Linear Regression Analysis

Calculated regression equation $y=0.9996 x+0.1277$

### 5.5.3. Statistical Analysis

The t-test was performed on the linear regression equations of the test system and the control system, and the $t$ value was $>t 0.05, \mathrm{P}<0.05$. There was a good linear relationship between the two groups of data, no significant difference.

### 5.6. Results Statistics and Analysis (CRE)

Data Mapping: Plot the difference between the measured value of the test system and the control system, and the measured value of the control system (the centre horizontal line is zero) and the measured system scatter plot (linear regression graph) of the test system and the control system. The results are shown below.


### 5.6.1. Visually Measure Linearity and Calculate Correlation Coefficient

The visual test system and the control system showed no outliers.
The correlation coefficient between the test system and the control system is calculated to be $r=0.9996$, which is greater than 0.975 . The range of values is appropriate and the correlation and consistency are good.

### 5.6.2. Linear Regression Analysis

Calculated regression equation $y=1.0001 x+1.229$

### 5.6.3. Statistical Analysis

The t-test was performed on the linear regression equations of the test system and the control system, and the $t$ value was $>t 0.05, \mathrm{P}<0.05$. There was a good linear relationship between the two groups of data, no significant difference.

### 5.7. Results Statistics and Analysis (GLU)

Data Mapping: Plot the difference between the measured value of the test system and the control system, and the measured value of the control system (the centre horizontal line is zero) and the measured system scatter plot (linear regression graph) of the test system and the control system. The results are shown below.


### 5.7.1. Visually Measure Linearity and Calculate Correlation Coefficient

The visual test system and the control system showed no outliers.
The correlation coefficient between the test system and the control system is $r=0.9932$, which is greater than 0.975 . The range of values is suitable and the correlation and consistency are good.

### 5.7.2. Linear Regression Analysis

Calculated regression equation $y=1.0032 x-0.0127$

### 5.7.3. Statistical Analysis

The t-test was performed on the linear regression equations of the test system and the control system, and the $t$ value was $>\mathrm{t0.05}, \mathrm{P}<0.05$. There was a good linear relationship between the two groups of data, no significant difference.
5.8. Results Statistics and Analysis (CK)

Data Mapping: Plot the difference between the measured value of the test system and the control system, and the measured value of the control system (the centre horizontal line is
zero) and the measured system scatter plot (linear regression graph) of the test system and the control system. The results are shown below.


5.8.1. Visually Measure Linearity and Calculate Correlation Coefficient

The visual test system and the control system showed no outliers.
The correlation coefficient between the test system and the control system is $r=0.9997$, which is greater than 0.975 . The range of values is suitable and the correlation and consistency are good.

### 5.8.2. Linear Regression Analysis

Calculated regression equation $y=1.0019 x+0.8671$

### 5.8.3. Statistical Analysis

The t-test was performed on the linear regression equations of the test system and the control system, and the $t$ value was $>\mathrm{t} 0.05, \mathrm{P}<0.05$. There was a good linear relationship between the two groups of data, no significant difference.

### 5.9. Results Statistics and Analysis (AST)

Data Mapping: Plot the difference between the measured value of the test system and the control system, and the measured value of the control system (the centre horizontal line is zero) and the measured system scatter plot (linear regression graph) of the test system and the control system. The results are shown below.


### 5.9.1. Visually Measure Linearity and Calculate Correlation Coefficient

The visual test system and the control system showed no outliers.
The correlation coefficient between the test system and the control system is calculated to be $r=0.9999$, which is greater than 0.975 . The range of values is appropriate and the correlation and consistency are good.

### 5.9.2. Linear Regression Analysis

Calculated regression equation $y=1 x+0.8035$

### 5.9.3. Statistical Analysis

The t-test was performed on the linear regression equations of the test system and the control system, and the $t$ value was $>t 0.05, \mathrm{P}<0.05$. There was a good linear relationship between the two groups of data, and there was no significant difference.

### 5.10. Results Statistics and Analysis (LDH)

Data Mapping: Plot the difference between the measured value of the test system and the control system, and the measured value of the control system (the centre horizontal line is zero) and the measured system scatter plot (linear regression graph) of the test system and the control system. The results are shown below.


### 5.10.1. Visually Measure Linearity and Calculate Correlation Coefficient

The visual test system and the control system showed no outliers.
The correlation coefficient between the test system and the control system is calculated to be $r=1$, which is greater than 0.975 . The range of values is appropriate and the correlation and consistency are good.

### 5.10.2. Linear Regression Analysis

Calculated regression equation $y=1.0022 x-0.4619$

### 5.10.3. Statistical Analysis

The t-test was performed on the linear regression equations of the test system and the control system, and the $t$ value was $>t 0.05, \mathrm{P}<0.05$. There was a good linear relationship between the two groups of data, and there was no significant difference.

## 6. Clinical Evaluation Conclusion

The test results show that the test system is equivalent to the control system and the correlation is good. There is no significant difference between the two test results and there is no significant deviation in clinical test.

WODDLEY
EQUIPMENT COMPANY LTD.

Old Station Park Buildings
St. John Street
Horwich
Bolton
BL6 7NY, UK
Tel: +44 (0) 1204669033
Email: sales@woodleyequipment.com
Web: www.woodleyequipment.com

